Gastrointestinal Bleeding Treatment Devices Market Report 2025

This Gastrointestinal Bleeding Treatment Devices market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The gastrointestinal bleeding treatment devices market size has grown strongly in recent years. It will grow from $0.87 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to aging population, lifestyle factors, healthcare infrastructure, gastrointestinal disorders, endoscopy advances.

The gastrointestinal bleeding treatment devices market size is expected to see strong growth in the next few years. It will grow to $1.3 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to patient-centric care, regulatory changes, telemedicine and remote consultations, increasing gastrointestinal disorders, healthcare investment. Major trends in the forecast period include non-invasive diagnostic technologies, non-invasive diagnostic technologies, precision medicine, remote monitoring and telehealth, artificial intelligence and machine learning.

The increasing incidence of upper gastrointestinal bleeding is anticipated to contribute to the growth of the gastrointestinal bleeding treatment devices market during the forecast period. Upper gastrointestinal (GI) bleeding, occurring in the esophagus, stomach, or upper part of the small intestine, can be attributed to various factors such as peptic ulcers, esophagitis, enteritis, gastritis, and cancer. For instance, the National Institute for Health and Care Excellence reports that the incidence of acute upper GI bleeding in the UK ranges from 84-172 per 100,000 of the population per year. Additionally, a study published in the National Library of Medicine - National Institutes of Health in 2023 reveals that in-hospital mortality rates for upper GI bleeds stand at approximately 10%, remaining consistent up to one month following hospitalization. Over the long term, three years after admission, mortality rates from all causes reach nearly 37%.

The rising prevalence of gastrointestinal disorders is anticipated to enhance the market's attractiveness. Gastrointestinal diseases may arise from factors such as a low-fiber diet, stress, insufficient water intake, high consumption of dairy products, a sedentary lifestyle, aging, and genetic predispositions. For example, in October 2024, the National Library of Medicine, a US-based national library, reported that in 2023, there were 825 cases per 100,000 Canadians diagnosed with inflammatory bowel disease (IBD), affecting over 320,000 individuals. Projections suggest that this number could increase to 1.1% of the population, approximately 470,000 Canadians, by 2035. Thus, the growing prevalence of disorders related to the gastrointestinal tract is propelling market growth.

Leading companies in the gastrointestinal bleeding treatment devices market are concentrating on developing advanced solutions, such as the EVIS X1 endoscopy system, to enhance diagnostic precision, improve patient outcomes, and optimize clinical workflows. The EVIS X1 endoscopy system is a sophisticated endoscopic imaging platform intended to boost diagnostic accuracy and therapeutic interventions across various medical fields, including gastroenterology, pulmonology, and urology. For example, in November 2023, Olympus Corporation, a Japan-based company specializing in medical and surgical technologies, introduced its next-generation EVIS X1 endoscopy system. This upgraded version represents a significant advancement in endoscopic imaging technology, aimed at enhancing diagnostic capabilities, improving procedural efficiency, and promoting better clinical outcomes. The new EVIS X1 builds on its predecessor by integrating state-of-the-art imaging techniques, user-friendly interfaces, and artificial intelligence (AI) support, specifically designed to meet a wide range of medical needs, particularly in gastroenterology and pulmonology.

Leading companies in the gastrointestinal bleeding treatment devices market are concentrating on developing advanced solutions, such as Hemospray, to improve the effectiveness of treating acute bleeding in the gastrointestinal (GI) tract. Hemospray is a hemostatic powder designed to manage and control active bleeding in the GI tract. For instance, in January 2024, AIG Hospitals, an India-based medical institution, introduced Hemospray, marking a significant advancement in controlling GI bleeding. This hemostatic agent is specifically designed for use in endoscopic procedures to manage acute gastrointestinal (GI) bleeding. Hemospray is recognized for its ease of use, safety profile, and effectiveness in controlling a wide range of GI bleeds, from peptic ulcers to variceal hemorrhages.

In June 2023, Merck, a US-based global pharmaceutical company, acquired Prometheus Biosciences, Inc. for $10.8 billion. This acquisition greatly strengthens Merck's position in the immunology sector, an area in which the company had previously been less active. Prometheus Biosciences, Inc. is a US-based biotechnology firm that specializes in the discovery, development, and commercialization of innovative precision therapies and diagnostics for patients with gastrointestinal (GI) and immune-mediated diseases.

Major companies operating in the gastrointestinal bleeding treatment devices market include CONMED Corporation, Boston Scientific Corporation, Ovesco Endoscopy AG, Olympus Corporation, Cook Medical, Erbe Elektromedizin GmbH, Steris plc., Medtronic, Johnson & Johnson, Abbott Laboratories, Fujifilm Holdings Corporation, Pentax Medical, Merit Medical Systems, Teleflex Incorporated, AngioDynamics, BTG International Ltd., Medline Industries Inc. Smiths Medical, Terumo Corporation, Nipro Corporation, ConvaTec Group PLC, Coloplast A/S, Hollister Incorporated, Wellspect HealthCare, C. R. Bard Inc., EndoChoice Holdings Inc., GI Supply Inc., Hemostasis LLC.

North America was the largest region in the gastrointestinal bleeding treatment devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal bleeding treatment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gastrointestinal bleeding treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Gastrointestinal (GI) bleeding serves as a symptom of an underlying illness where the gastrointestinal system experiences bleeding. The bleeding can manifest in various parts of the gastrointestinal tract, encompassing the large intestine, anus, esophagus, small intestine, rectum, and stomach.

In the gastrointestinal bleeding treatment devices market, the primary types of products include endoscopic mechanical devices, endoscopic thermal devices, and others. Endoscopic mechanical devices play a crucial role in managing GI arterial bleeding and comprise hemostatic clips, also known as through-the-scope (TTS) clips, endoscopic detachable snare ligation (EDSL) devices, endoscopic suturing, and over-the-scope clips (OTSC). These devices are subject to review for their technological applications and clinical utility. The segmentation of the gastrointestinal bleeding treatment devices market includes divisions based on the GI tract, distinguishing between the lower GI tract and upper GI tract. Additionally, these devices find application in various healthcare settings, such as hospitals or clinics, ambulatory surgical centers, and other medical facilities.

The gastrointestinal bleeding treatment market research report is one of a series of new reports that provides gastrointestinal bleeding treatment market statistics, including gastrointestinal bleeding treatment industry global market size, regional shares, competitors with a gastrointestinal bleeding treatment market share, detailed gastrointestinal bleeding treatment market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal bleeding treatment industry. This gastrointestinal bleeding treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastrointestinal bleeding treatment devices market consists of sales of thermal therapy, multipolar electrocoagulation probe, heater probe, hemostatic foreceps, and argon plasma coagulation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.